SOS1

nwamba # Aha ngwaahịa Nkọwa
CPD10000 BI-3406 BI-3406 nwere ike & Nhọrọ SOS1 :: KRAS Inhibitor (IC50=5 nM), nke na-emepe Ụzọ Ọhụrụ maka ọgwụgwọ Tumours-KRAS. BI 3406 na-ahọrọ nke ọma na SOS1 ma gbochie mmekọrịta ya na KRAS, n'agbanyeghị ngbanwe KRAS. BI 3406 na-ebute mbelata RAS GTP na PERK ma na-egbochi uto cell nke ahịrị cell mutated KRAS, na-ebu ọtụtụ ngbanwe nke KRAS (ya bụ G12D, G12V, G13D na ndị ọzọ). BI 3406, mgbe a na-enye ya ọnụ na oke ndị na-ebu etuto ahụ, na-ebute nsonaazụ dabere tumor static mmetụta nke enwere ike ịtụgharị ka ọ bụrụ nkwụghachi azụ mgbe ejikọtara ya na mgbochi MEK1.
CPD2807 BAY-293 BAY-293 bụ ihe mgbochi SOS1 siri ike nke na-egbochi ịgbalite RAS site na imebi mmekọrịta RAS-SOS1. BAY-293) na-akpachapụ anya na-egbochi mmekọrịta KRAS-SOS1 na IC50 nke 21 nM ma bụrụ nyocha kemịkalụ bara uru maka nyocha n'ọdịnihu.
nke

Kpọtụrụ anyị

Ajuju

Akụkọ kacha ọhụrụ

  • Usoro 7 kachasị na nyocha ọgwụ na 2018

    Usoro 7 kacha elu na nyocha ọgwụ m...

    N'ịbụ ndị nọ n'okpuru nrụgide na-arịwanye elu mgbe niile ịsọ mpi na gburugburu ebe obibi akụ na ụba na nkà na ụzụ siri ike, ụlọ ọrụ ọgwụ na biotech ga-anọgide na-emepe emepe na mmemme R&D ha iji nọgide na-aga n'ihu ...

  • ARS-1620: Onye mmechi ọhụrụ na-ekwe nkwa maka ọrịa cancer KRAS-mutant

    ARS-1620: ihe mgbochi ọhụrụ na-ekwe nkwa maka K…

    Dị ka otu nnyocha e bipụtara na Cell si kwuo, ndị nchọpụta ewepụtala ihe mgbochi kpọmkwem maka KRASG12C nke a na-akpọ ARS-1602 nke na-eme ka ụbụrụ tumor regression na ụmụ oke. "Ọmụmụ ihe a na-enye na vivo ihe akaebe na mutant KRAS nwere ike ịbụ ...

  • AstraZeneca na-enweta nkwalite nchịkwa maka ọgwụ oncology

    AstraZeneca na-enweta nkwalite nchịkwa maka ...

    AstraZeneca nwetara nkwalite okpukpu abụọ maka pọtụfoliyo oncology ya na Tuesday, mgbe ndị na-ahụ maka US na European nabatara ntinye iwu maka ọgwụ ya, nzọụkwụ mbụ iji nweta nkwado maka ọgwụ ndị a. ...

Mkparịta ụka WhatsApp n'ịntanetị!